Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi purchased 22,053,581 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was bought at an average price of $0.91 per share, for a total transaction of $20,068,758.71. Following the purchase, the director now directly owns 24,847,694 shares in […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi acquired 22,053,581 shares of Satsuma Pharmaceuticals stock in a transaction dated Tuesday, June 6th. The shares were purchased at an average price of $0.91 per share, with a total value of $20,068,758.71. Following the acquisition, the director now owns 24,847,694 shares of the company’s stock, […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 159,400 shares, a decrease of 40.4% from the March 15th total of 267,500 shares. Based on an average daily trading volume, of 152,700 shares, the short-interest ratio […]
Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, The Fly reports. Separately, Mizuho restated a “neutral” rating and set a $2.00 price objective on shares of Satsuma Pharmaceuticals in a […]